Aspen Pharmacare results lift EBITDA and NHEPS on efficiency, APAC divestment
Aspen Pharmacare reported strong EBITDA and NHEPS growth with flat revenue, citing Commercial Pharma and efficiency gains. APAC divestment unlocked value, strengthened the balance sheet, and GLP-1s plus Sterile FDF are set to drive future growth.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.